{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-118699","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.214991+00:00","generated_at":"2026-05-15T09:23:15.775847+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman","bullets":["Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.","Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.","New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).","Peter Harwin named Chairman of the Board.","Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-118699","json":"https://secwatch.observer/filing/0001193125-26-118699.json","markdown":"https://secwatch.observer/filing/0001193125-26-118699.md","text":"https://secwatch.observer/filing/0001193125-26-118699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/0001193125-26-118699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/dmra-20260320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:23:15.775847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}